Toronto Stocks Advance; Couche-Tard Slides on 3Q Profit, Revenue Declines
By Adriano Marchese
Stocks in Toronto were firmly higher mid-trading on Thursday. Most sectors were higher in the session, driven by the tech sector, health services and producer manufacturing stocks. The gains were partially offset by declines in retail, health tech and energy stocks.
At midday, Canada's S&P/TSX Composite Index climbed 0.45% to 22144.76.
The blue-chip S&P/TSX 60 rose by 0.51% to 1334.56.
Shares of Alimentation Couche Tard were 3.4% lower at 78.78 Canadian dollars ($58.39) after the Canadian convenience-store operator company said its third-quarter profit and revenue fell as consumers reigned in their spending.
Other market movers:
WELL Health Technologies shares were lower by over 10% to C$3.81 despite posting better-than-expected revenue and in-line adjusted earnings in the fourth quarter. The Canadian health technology company also upgraded its outlook for 2024.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 21, 2024 12:15 ET (16:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks